ACXP — Acurx Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $10.78m
- $4.71m
Annual income statement for Acurx Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.6 | 12.7 | 12.1 | 14.6 | 14.1 |
| Operating Profit | -4.6 | -12.7 | -12.1 | -14.6 | -14.1 |
| Net Income Before Taxes | -4.6 | -12.7 | -12.1 | -14.6 | -14.1 |
| Net Income After Taxes | -4.6 | -12.7 | -12.1 | -14.6 | -14.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -4.6 | -12.7 | -12.1 | -14.6 | -14.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -4.6 | -12.7 | -12.1 | -14.6 | -14.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -9.64 | -30 | -22.4 | -23 | -17.5 |
| Dividends per Share |